The Renaissance deputy for Hautes-Pyrénées, Benoît Mournet, proposes to regulate the installation of doctors

the essential The Renaissance deputy for Hautes-Pyrénées Benoît Mournet proposes to regulate the installation of doctors in order to offer a better geographical distribution of practitioners. Amendments which will be studied as part of the vote on the bill on access to care through the territorial commitment of professionals. Increase in places in nursing institutes, … Read more

Marciac. The health antenna starts – ladepeche.fr

Thursday, June 1, the departmental council represented by Jérôme Samalens, in charge of the fight against medical desertification, brought together the health professionals of Marciac in order to present the device of the territorial health centers, (CTS) and the health antenna of Marciac. Dependent on the territorial center of Plaisance, it will be functional from … Read more

Onet-le-Chateau. Another great gourmet evening for members of the Scalene

Last Wednesday, the members of the “Le Scalène” green cooking club welcomed Sandrine Jany, producer and processor of aromatic and medicinal plants (who can also be found on the markets of Rodez, Decazeville or Cransac), for a performance-demonstration highly appreciated by the fifteen or so members present. Pleasure syrups (mint, dandelion, verbena, acacia, etc.), herbal … Read more

Innovent Updates Phase 1b Data of IBI939 (Anti-TIGIT Monoclonal Antibody) Combined with Sintilimab in Previously Untreated PD-L1-selected NSCLC at the 2023 ASCO Annual Meeting

ROCKVILLE, Md. and SUZHOU, China, June 3, 2023 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, updated the Phase 1b efficacy and safety results of IBI939 (anti-TIGIT antibody) combined with sintilimab (anti-PD-1 … Read more

Janssen Presents Longer-Term Talquetamab Follow-Up Data Showing Overall Response Rates of More Than 70 Percent in Heavily Pretreated Patients with Multiple Myeloma

Additional long-term data from the TRiMM-2 study in patients receiving talquetamab and DARZALEX FASPRO® combination biweekly regimen showed an overall response rate of more than 80 percent CHICAGO, June 3, 2023 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the pivotal Phase 1/2 MonumenTAL-1 study of the investigational … Read more

Janssen Presents First-Ever Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients with Relapsed or Refractory Multiple Myeloma

CHICAGO, June 3, 2023 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first-ever results from the Phase 1b RedirecTT-1 study of TECVAYLI® (teclistamab-cqyv), a first-in-class BCMAxCD3 bispecific antibody, and talquetamab, a first-in-class GPRC5DxCD3 bispecific antibody, showing a high overall response rate (ORR) among patients with relapsed or refractory multiple myeloma (RRMM).1 … Read more

Gracell Biotechnologies Presents Updated Data of Deep and Durable Responses for FasTCAR-T GC012F in Relapsed/Refractory Multiple Myeloma at 2023 ASCO Annual Meeting

Data on BCMA/CD19 dual-targeting FasTCAR-T GC012F showed 100% minimal residual disease (MRD) negativity and 82.8% MRD negative stringent complete response (sCR) in a predominantly high-risk relapsed/refractory multiple myeloma (RRMM) population Data on GC012F for treatment of B-NHL will be presented on June 5 in a poster presentation at 2023 ASCO Annual Meeting SAN DIEGO, Calif., … Read more